Trandolapril decreases prevalence of ventricular ectopic activity in middle-aged SHR.
BACKGROUND
Although severe arrhythmias are still a major problem in patients with left ventricular hypertrophy (LVH), the relationship between ventricular remodeling and its regression or prevention, and the prevalence of ventricular premature beats (VPB) or more sustained arrhythmias are still poorly explored in hypertensive heart disease.


RESULTS
Holter monitoring was used to quantify supraventricular premature beats and VPB and heart rate (HR) in middle-aged spontaneously hypertensive rats (SHR) and Wistar rats treated for 3 months with trandolapril (ACE inhibitor, 0.3 mg/kg per day). Hypertrophy and fibrosis were morphometrically determined. Statistical analysis was performed with the use of simple regression and multivariate data analysis (cluster and correspondence analysis). SHR have higher cardiac mass and fibrosis, more VPB, and a decreased HR. Cluster analysis demonstrated that trandolapril was only effective in SHR. Trandolapril significantly reduced cardiac hypertrophy, fibrosis, and VPB incidence and increased the HR. Simple regression analysis showed that VPB incidence correlated to both hypertrophy and fibrosis. Correspondence analysis evidenced a strong correlation between hypertrophy, fibrosis, and VPB, but only for severe hypertrophy, and the correlation disappeared for moderate hypertrophy.


CONCLUSIONS
After trandolapril treatment, the regression of VPB incidence not only is linked to hypertrophy and fibrosis, but additional causal factors also are involved including the myocardial phenotype and new calcium metabolism. Our model of Holter monitoring in conscious middle-aged SHR and multivariate data analysis might be useful in correlating myocardial structural modifications and ectopic activity.
Chevalier
B
B
INSERM-U127, Hôpital Lariboisière, Paris, France.
Heudes
D
D
Heymes
C
C
Basset
A
A
Dakhli
T
T
Bansard
Y
Y
Jouquey
S
S
Hamon
G
G
Bruneval
P
P
Swynghedauw
B
B
D000375:Aging; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D005117:Cardiac Complexes, Premature / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D015716:Electrocardiography, Ambulatory / Q000379:methods / Q000662:veterinary; D004719:Endomyocardial Fibrosis / Q000209:etiology / Q000517:prevention & control; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D017379:Hypertrophy, Left Ventricular / Q000209:etiology / Q000517:prevention & control; D015994:Incidence; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D015999:Multivariate Analysis; D015995:Prevalence; D051381:Rats; D011918:Rats, Inbred SHR; D017208:Rats, Wistar
D000806:Angiotensin-Converting Enzyme Inhibitors; D007211:Indoles; C052035:trandolapril